An observational study in Knee Osteoarthritis, sponsored by Sisli Hamidiye Etfal Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Sisli Hamidiye Etfal Training and Research Hospital · Observational
This study evaluates how acute mechanical loading affects cartilage degradation biomarkers in postmenopausal women with mild-to-moderate knee osteoarthritis. Participants will be grouped according to their existing antiresorptive treatment status: denosumab users, bisphosphonate users, and a control group. All participants will undergo a 30-minute treadmill walking session at a comfortable and tolerated speed. Blood samples will be collected immediately before and within 0-2 minutes after walking to measure changes in cartilage degradation biomarkers, including cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase-3 (MMP-3). The study aims to determine whether the biomarker response to acute mechanical loading differs according to antiresorptive treatment status.
3,391 studies on the registry are indexed under Osteoarthritis, Knee; 628 are open to participants now.
This study's planned enrollment of 105 is close to the median of 100 across 484 observational studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →Sisli Hamidiye Etfal Training and Research Hospital is the lead sponsor of 113 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Postmenopausal women aged 60-80 years with clinically and radiographically confirmed knee osteoarthritis who meet the protocol-defined eligibility criteria. Participants are categorized according to their existing antiresorptive treatment status into denosumab, bisphosphonate, and control groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Postmenopausal women aged 60-80 years with DEXA-confirmed osteoporosis and clinically and radiographically confirmed knee osteoarthritis who have been regularly receiving denosumab for at least 12 months, with the last dose administered 2-4 months before the study assessment.
Postmenopausal women aged 60-80 years with DEXA-confirmed osteoporosis and clinically and radiographically confirmed knee osteoarthritis who have been regularly receiving the same bisphosphonate for at least 12 months.
Postmenopausal women aged 60-80 years with DEXA-confirmed osteopenia and clinically and radiographically confirmed knee osteoarthritis who are not currently receiving antiresorptive treatment and have either never used antiresorptive treatment or discontinued bisphosphonate treatment at least 5 years ago.
Change in serum COMP levels from T0 to T1 comparing denosumab and bisphosphonate groups
Change in serum cartilage oligomeric matrix protein (COMP) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving denosumab with those receiving bisphosphonate treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
Change in serum MMP-3 levels from T0 to T1 comparing denosumab and bisphosphonate groups
Change in serum matrix metalloproteinase-3 (MMP-3) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving denosumab with those receiving bisphosphonate treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
Change in serum COMP levels from T0 to T1 comparing denosumab and control groups
Change in serum cartilage oligomeric matrix protein (COMP) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving denosumab with the control group not receiving current antiresorptive treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
Change in serum MMP-3 levels from T0 to T1 comparing denosumab and control groups
Change in serum matrix metalloproteinase-3 (MMP-3) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving denosumab with the control group not receiving current antiresorptive treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
Change in serum COMP levels from T0 to T1 comparing bisphosphonate and control groups
Change in serum cartilage oligomeric matrix protein (COMP) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving bisphosphonate treatment with the control group not receiving current antiresorptive treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
Change in serum MMP-3 levels from T0 to T1 comparing bisphosphonate and control groups
Change in serum matrix metalloproteinase-3 (MMP-3) levels from immediately before acute mechanical loading (T0) to immediately after the loading protocol (T1), comparing participants receiving bisphosphonate treatment with the control group not receiving current antiresorptive treatment.
Time frame: Immediately before and within 0-2 minutes after the 30-minute treadmill walking session
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sisli Hamidiye Etfal Training and Research Hospital →